Analysis of immune check point of musculoskeltal tumor

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K19993
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Orthopaedic surgery
• Research Institution: Mie University
• Principal Investigator: TAKUYA KAKIMOTO 三重大学, 医学系研究科, リサーチアソシエイト (50741162)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: soft tissue sarcoma / cancer testis antigen / NY-ESO-1 / MAGE-A4

Outline of Final Research Achievements

Immune check point such as Cancer testis antigens (CTA) have emerged over the last decade as both a diagnostic marker and a therapeutic target in malignant lesions. Recently, aberrant expression of PD-1, PD-L1, NY-ESO-1 and MAGE-A4 has been reported in a variety of neoplasms. However, there is only a limited report about those expression in high grade sarcoma. The purpose of this study is to examine those expression in high-grade soft tissue sarcomas and to evaluate the relationship between CTA expression and the various clinicopathological features. In this study, it was found that PD-L1 was expressed in soft tissue tumors and the NY-ESO-1 was expressed in more than half of samples of synovial sarcoma patients. The 5-years-overall survival rates were significantly higher in high grade sarcoma patients with NY-ESO-1 positive tumors than in those with NY-ESO-1 negative. Furthermore, we showed the MAGE-A4 was expressed only in more than half of synovial sarcoma patients.

Free Research Field

整形外科